

Glepaglutide

Cat. No.:	HY-P2221
CAS No.:	914009-86-2
Molecular Formula:	C ₁₉₇ H ₃₂₅ N ₅₃ O ₅₅
Molecular Weight:	4316.08
Sequence:	His-Gly-Glu-Gly-Thr-Phe-Ser-Ser-Glu-Leu-Ala-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Lys-Lys-Lys-Lys-Lys-Lys-NH ₂
Sequence Shortening:	HGEGTFSSELATILDALAARDFIWLIATKITDKKKKKK-NH ₂
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn's disease ^{[1][2][3]} .	
IC ₅₀ & Target	GLP-2R ^[3]	
In Vivo	Glepaglutide (200 and 400 nmol/kg, s.c., twice a day for 14 days) shows intestinotrophic effect in rats with small intestinal inflammation ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Rats with Indomethacin (HY-14397)-induced small intestinal inflammation ^[3]
	Dosage:	200 and 400 nmol/kg
	Administration:	Subcutaneous injection (s.c.), twice a day for 14 days.
	Result:	Increased plasma citrulline concentration. Increased small intestinal mass. Decreased small intestinal concentrations of the inflammatory marker (AGP and MPO).

REFERENCES

- [1]. Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. *Lancet Gastroenterol Hepatol.* 2019 May;4(5):354-363.
- [2]. Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. *Aliment Pharmacol Ther.* 2013 Jan;37(1):18-36.
- [3]. Jolanta Skarbalienė, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. *Gastroenterology*, 2011, 140(5): S519.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA